Dlaczego zaleca się stosowanie rasagiliny przed włączeniem lewodopy u pacjentów z chorobą Parkinsona? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2018
Słowa kluczowe:
rasagilina, choroba Parkinsona, monoterapia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Rasagilina jest nieodwracalnym, selektywnym inhibitorem MAO-B drugiej generacji. Jej skuteczność w monoterapii wczesnej choroby Parkinsona (ChP) została dobrze potwierdzona w badaniach klinicznych, chociaż jej objawowy efekt jest zwykle niewielki. Wczesne rozpoczynanie leczenia rasagiliną wiąże się z poprawą wyników długoterminowych w porównaniu z terapią odroczoną. Wcześniejsze badania wykazały, że rasagilina może być czynnikiem neuroprotekcyjnym, jednakże jej neuroprotekcyjne właściwości nie zostały jednoznacznie potwierdzone. Rasagilina zajmuje istotne miejsce w terapii osób z wczesną ChP.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Gorzkowska, A. (2018). Dlaczego zaleca się stosowanie rasagiliny przed włączeniem lewodopy u pacjentów z chorobą Parkinsona? . Medycyna Faktów , 11(4(41), 279-282. https://doi.org/10.24292/01.MF.0418.3
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Finberg J.P., Lamensdorf I., Commissiong J.W. et al.: Pharmacology and neuroprotective properties of rasagiline. J. Neural. Transm. Suppl. 1996; 48: 95-101.
2. Bar-Am O., Amit T., Youdim M.B.: Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J. Neurochem. 2007; 103: 500-508.
3. Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease. The TEMPO Study. Arch. Neurol. 2002; 59: 1937-1943.
4. Masselis M., Collinson S., Freeman N. et al.: Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain 2016; 139(Pt 7): 2050-2062.
5. Ferreira J.J., Katzenschlager R., Bloem B.R. et al.: Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur. J. Neurol. 2013; 20: 5-15.
6. Maruyama W., Akao Y., Carrillo M.C. et al.: Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 2002; 24: 675-682.
7. Finberg J.P., Takeshima T., Johnston JM. et al.: Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 1998; 9: 703-707.
8. Jenner P., Langston J.W.: Explaining ADAGIO – a critical review of biological basis for the clinical effects of rasagiline. Mov. Disord. 2011; 26: 2316-2323.
9. Heikkila R.E., Duvoisin R.C., Finberg J.P. et al.: Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 1985; 116: 313-317.
10. Blandini F., Armentero M.T., Fancellu R. et al.: Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Exp. Neurol. 2004; 187: 455-459.
11. Parkinson Study Group: A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 2004; 61: 561-566.
12. Olanow C.W., Stern M.B., Sethi K.: The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009; 72(21 Supl. 4): S1-136.
13. Dietrichs E., Odin P.: Algorithms for the treatment of motor problems in Parkinson’s disease. Acta Neurol. Scand. 2017; 136(5): 378-385.
14. Olanow C.W., Rascol O., Hauser R. et al.: A double-blind, delayed start trial of rasagilline in Parkinson’s disease. N. Engl. J. Med. 2009; 361(13): 1268-1278.
15. Rascol O., Fitzer-Attas C.J., Hauser R. et. al.: A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011; 10(5): 415-423.
16. Jankovic J., Berkovich E., Eyal E. et al.: Symptomatic efficacy of rasagiline monotherapy in early Parkinson’s disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat. Disord. 2014; 20(6): 640-643.
17. Rascol O., Hauser R., Stocchi F. et al.: Long-term effects of rasagilline and nat ural history of treated Parkinson’s disease. Mov. Disord. 2016; 31: 1489-1496.
18. Opala G., Gorzkowska A.: Rasagilina – nowa opcja leczenia choroby Parkinsona. Neurologica 2005; 1(13): 29-32, 40.
2. Bar-Am O., Amit T., Youdim M.B.: Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J. Neurochem. 2007; 103: 500-508.
3. Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease. The TEMPO Study. Arch. Neurol. 2002; 59: 1937-1943.
4. Masselis M., Collinson S., Freeman N. et al.: Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain 2016; 139(Pt 7): 2050-2062.
5. Ferreira J.J., Katzenschlager R., Bloem B.R. et al.: Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur. J. Neurol. 2013; 20: 5-15.
6. Maruyama W., Akao Y., Carrillo M.C. et al.: Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 2002; 24: 675-682.
7. Finberg J.P., Takeshima T., Johnston JM. et al.: Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 1998; 9: 703-707.
8. Jenner P., Langston J.W.: Explaining ADAGIO – a critical review of biological basis for the clinical effects of rasagiline. Mov. Disord. 2011; 26: 2316-2323.
9. Heikkila R.E., Duvoisin R.C., Finberg J.P. et al.: Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 1985; 116: 313-317.
10. Blandini F., Armentero M.T., Fancellu R. et al.: Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Exp. Neurol. 2004; 187: 455-459.
11. Parkinson Study Group: A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 2004; 61: 561-566.
12. Olanow C.W., Stern M.B., Sethi K.: The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009; 72(21 Supl. 4): S1-136.
13. Dietrichs E., Odin P.: Algorithms for the treatment of motor problems in Parkinson’s disease. Acta Neurol. Scand. 2017; 136(5): 378-385.
14. Olanow C.W., Rascol O., Hauser R. et al.: A double-blind, delayed start trial of rasagilline in Parkinson’s disease. N. Engl. J. Med. 2009; 361(13): 1268-1278.
15. Rascol O., Fitzer-Attas C.J., Hauser R. et. al.: A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011; 10(5): 415-423.
16. Jankovic J., Berkovich E., Eyal E. et al.: Symptomatic efficacy of rasagiline monotherapy in early Parkinson’s disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat. Disord. 2014; 20(6): 640-643.
17. Rascol O., Hauser R., Stocchi F. et al.: Long-term effects of rasagilline and nat ural history of treated Parkinson’s disease. Mov. Disord. 2016; 31: 1489-1496.
18. Opala G., Gorzkowska A.: Rasagilina – nowa opcja leczenia choroby Parkinsona. Neurologica 2005; 1(13): 29-32, 40.